The Latest
-
J&J exec: Our coronavirus vaccine is aiming for a 70% success rate in trials
-
Barstool Sports’ Dave Portnoy Is Leading an Army of Day Traders
-
Regeneron Starts Human Clinical Trials Of Covid-19 Antibody Cocktail
-
Is There An Opportunity With Ocular Therapeutix, Inc.’s (NASDAQ:OCUL) 46% Undervaluation?